Overview

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

Status:
Completed
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
This pilot clinical trial studies vorinostat in treating patients with stage IV breast cancer receiving hormone therapy. Vorinostat may help hormone therapy work better by making tumor cells more sensitive to the drug.
Phase:
N/A
Details
Lead Sponsor:
University of Washington
Collaborator:
National Cancer Institute (NCI)
Treatments:
Anastrozole
Estradiol
Exemestane
Fluorodeoxyglucose F18
Letrozole
Vorinostat